Semax is a lab-made peptide — a short chain of amino acids, the building blocks of proteins — that Russian scientists copied from a fragment of the stress hormone ACTH and then deliberately stripped of its hormone activity. What is left is a molecule studied for the brain: focus, memory, and protection of neurons after injury, without the cortisol surge ACTH itself causes. It is an approved medicine in Russia and a research compound almost everywhere else.
In plain terms: it borrows a piece of a stress hormone, throws away the "stress" part, and keeps a brain-support signal.
What it is
Semax is a heptapeptide — exactly seven amino acids (Met-Glu-His-Phe-Pro-Gly-Pro). The first four come from the natural sequence of ACTH (adrenocorticotropic hormone), specifically the ACTH(4-7) region. The last three — Pro-Gly-Pro — are a small tail the chemists added on purpose. That tail acts like a bumper: it slows the enzymes that would otherwise chop the peptide apart, so Semax survives a little longer than the raw fragment would3.
Crucially, the piece of ACTH that Semax keeps is the behavioural part, not the hormonal part. So unlike ACTH, Semax does not tell the adrenal glands to release cortisol. That separation — brain effects without the stress-hormone effects — is the whole design idea.
Here is the pharmacology at a glance:
| Property | Semax |
|---|---|
| Type | Synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) |
| Parent molecule | ACTH(4-7) fragment, plus a Pro-Gly-Pro stabiliser tail |
| Proposed action | Raises BDNF and NGF; activates dopamine and serotonin systems |
| Typical research route | Intranasal (nose drops / spray) |
| Plasma half-life | Minutes (very short) |
| Regulatory status | Approved medicine in Russia; not FDA-approved (research compound) |
How it's thought to work
The leading explanation is neurotrophins — the body's "keep neurons alive and growing" signals. The most-cited is BDNF (brain-derived neurotrophic factor); think of it as fertiliser for brain cells. In a rat study, a single dose of Semax raised BDNF protein in the hippocampus (the brain's memory hub) and increased its partner receptor, trkB, within hours3.
Semax also stirs the brain's chemical messengers. In rodents it activated the dopaminergic and serotonergic systems — the dopamine and serotonin pathways tied to motivation, mood, and attention2. And after a simulated stroke in rats, Semax switched on the genes that make neurotrophins and their receptors, which fits its use as a neuroprotective (nerve-protecting) drug5.
In plain terms: in animals it looks like a growth-and-repair signal for neurons, paired with a gentle nudge to the brain chemicals behind focus and mood. Important flag: these are animal and cell findings — a strong lead, not proof of the same effect in people.
How long it lasts
Semax clears the blood fast — its plasma half-life (the time for half a dose to disappear from the bloodstream) is measured in minutes, because enzymes break the peptide down quickly. That sounds like a problem, but it is why the route matters: Semax is studied as an intranasal peptide (drops or spray in the nose). The nasal route is thought to deliver it toward the brain more directly, and its measured effects — on gene activity and behaviour — appear to outlast the few minutes it spends in the blood.
In plain terms: the blood level vanishes quickly, but the effect it kicks off seems to linger.
What the studies actually found
Semax's reputation rests on a mix of rat mechanism studies and Russian human trials. Here they are in order, with the model each used, so you can see how the picture built up — and where the honesty flags sit:
| Study | Model | Key result | Year |
|---|---|---|---|
| Gusev & Skvortsova et al.1 | Human (acute stroke, small) | Intranasal Semax added to care was linked to faster recovery of neurological deficits vs controls | 2001 |
| Eremin et al.2 | Rat + mouse | Activated dopamine and serotonin systems; boosted the effect of amphetamine on dopamine release | 2005 |
| Dolotov et al.3 | Rat (hippocampus) | A single dose raised BDNF protein and trkB receptor activity within hours | 2006 |
| Gusev & Martynov et al.4 | Human (110 stroke patients) | Semax raised plasma BDNF and improved motor scores and daily-function (Barthel) scores over months | 2018 |
| Filippenkov et al.5 | Rat (cerebral ischemia) | Switched on neurotrophin and receptor genes in the injured brain — a mechanism for its stroke use | 2024 |
Read the two human rows carefully. They are genuinely encouraging — patients getting Semax alongside standard stroke care recovered faster in these studies14. But both are Russian trials, one of them small, and neither is the kind of large, independent, placebo-controlled study that would settle the question for Western regulators.
The honest catch: whose evidence is it?
This is the part vendor pages blur, so plainly: Semax is an approved drug in Russia, where it has been used since the 1990s and has a real clinical track record in stroke and cognition. But that evidence is almost entirely Russian, much of it in Russian-language journals, and a lot of it is small or not blinded to modern standards. It has not been independently replicated in large Western randomized controlled trials.
That does not make the Russian data fake — it makes it *unconfirmed elsewhere*. The animal mechanism (BDNF, dopamine, neurotrophin genes) is consistent and interesting. The human proof, by the standard the rest of this site holds compounds to, is still thin outside one country.
In plain terms: approved and used in Russia, unproven by Western-trial standards.
Regulatory status
Semax is not an approved medicine in the United States or the EU. In the US it appeared on the FDA's interim Category 2 list of bulk substances for compounding pharmacies — a "needs further evaluation" bin. In 2026 that status entered active review, with peptides in this group flagged for possible reclassification, so treat the exact rule as a moving snapshot rather than a settled one. This page takes no position on where anyone obtains anything and never discusses sourcing.
Latest research
- The 2024 Filippenkov study is the freshest mechanistic work: in a rat stroke model, Semax (and its Pro-Gly-Pro tail alone) switched on neurotrophin and receptor genes in injured brain tissue — a molecular reason for the neuroprotective claim5.
- The 2018 Gusev human trial remains the most concrete recent human signal: 110 stroke patients, higher plasma BDNF, and better motor and daily-function scores with Semax added to rehabilitation4.
- The live story is regulatory — the 2026 FDA review of these peptides is the thing most likely to change next. We update this section as new studies and decisions land.
The short version
Semax is a small, durable brain-active peptide built from a fragment of ACTH, minus the hormone effect. In animals it raises BDNF and stirs the dopamine and serotonin systems; in Russia it is an approved intranasal medicine for stroke and cognition. The honest limit is the evidence base: it is almost all Russian, often small, and not replicated in large Western trials — so it is best understood as *promising and clinically used in one country, unconfirmed elsewhere*. This is an educational overview, not medical advice. Its usual companion in the Russian nootropic story is Selank; for the wider map, see what are research peptides.